Cortisol release from adipose tissue by 11 β-hydroxysteroid dehydrogenase type 1 in humans

Diabetes

Volumn 58, Issue 1, 2009, Pages 46-53

  Stimson, Roland H ^a   Andersson, Jonas ^b   Andrew, Ruth ^a   Redhead, Doris N ^c   Karpe, Fredrik ^d   Hayes, Peter C ^c   Olsson, Tommy ^b   Walker, Brian R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; DEUTERIUM; HYDROCORTISONE;

ADIPOSE TISSUE; ADULT; AGED; ANTHROPOMETRY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYDROCORTISONE RELEASE; ISOTOPE LABELING; MALE; OBESITY; PORTAL VEIN; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW; SUBCUTANEOUS FAT; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; LIVER; METABOLISM; MIDDLE AGED;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ADULT; AGED; HUMANS; HYDROCORTISONE; LIVER; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; OBESITY; SPLANCHNIC CIRCULATION; YOUNG ADULT;

EID: 63249083541     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-0969     Document Type: Article

References (41)

1. Macfarlane DP, Forbes S, Walker BR: Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197:189-204, 2008
2. Seckl JR, Walker BR: 11β-Hydroxysteroid dehydrogenase type 1: a tissue- specific amplifier of glucocorticoid action. Endocrinology 142:1371-1376, 2001
3. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM: 11Beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866, 2004
4. Bujalska IJ, Kumar S, Stewart PM: Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 349:1210-1213, 1997
5. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR: Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11p-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54:872-879, 2005
6. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DEW, Johnson O, Walker BR: Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421, 2001
7. Walker BR: Glucocorticoids and cardiovascular disease. Eur J Endocrinol 157:545-559, 2007
8. Hughes KA, Webster SP, Walker BR: 11-Beta-hydroxysteroid dehydroge-nase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs 17:481-496, 2008
9. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170, 2001
10. Katz JR, Mohamed-Ali V, Wood PJ, Yudkin JS, Coppack SW: An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin Endocrinol 50:63-68, 1999
11. Wake DJ, Stimson RH, Tan GD, Homer NZ, Andrew R, Karpe F, Walker BR: Effects of peroxisome proliferator-activated receptor (PPAR) {alpha} and {gamma} agonists on 11{beta}-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. J Clin Endocrinol Metab 92:1848-1856, 2007
12. Aldhahi W, Mun E, Goldfine AB: Portal and peripheral cortisol levels in obese humans. Diabetologia 47:833-836, 2004
13. Tarantino G, Lobello R, Scopacasa F, Contaldo F, Pasanisi F, Cirillo M, De Caterina M, Conca P, Terracciano D, Gennarelli N, Ariello M, Mazzarella C, Grimaldi E, Macchia V: The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome. Clin Invest Med 30:E192-E199, 2007
14. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CRW: Mineralo-corticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 27:483-492, 1992
15. Andrew R, Smith K, Jones GC, Walker BR: Distinguishing the activities of 11beta-hydroxysteroid dehydrogenases in vivo using isotopically labelled cortisol. J Clin Endocrinol Metab 87:277-285, 2002
16. Andrew R, Westerbacka J, Wahren J, Yki-Jarvinen H, Walker BR: The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 54:1364-1370, 2005
17. Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson CM, Toffolo G, Cobelli C, Rizza RA: Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydrox-ysteroid dehydrogenase (11beta-hsd) type 1 pathway. Diabetes 53:2051-2059, 2004
18. Basu R, Edgerton DS, Singh RJ, Cherrington A, Rizza RA: Splanchnic cortisol production in dogs occurs primarily in the liver: evidence for substantial hepatic specific 11{beta} hydroxysteroid dehydrogenase type 1 activity. Diabetes 55:3013-3019, 2006
19. Coppack SW, Fisher RM, Gibbons GF, Humphreys SM, McDonough MJ, Potts JL, Frayn KN: Postprandial substrate deposition in human forearm and adipose tissues in vivo. Clin Sci (Lond) 79:339 -348, 1990
20. Larsen OA, Lassen NA, Quaade F: Blood flow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand 66:337-345, 1966
21. Samra JS, Frayn KN, Giddings JA, Clark ML, MacDonald IA: Modification and validation of a commercially available portable detector for measurement of adipose tissue blood flow. Clin Physiol 15:241-248, 1995
22. Burns E, Triger DR, Tucker GT, Bax ND: Indocyanine green elimination in patients with liver disease and in normal subjects. Clin Sci (Lond) 80:155-160, 1991
23. Wolfe RL, Chinkes DL: Arterial-venous balance technique to measure amino acid kinetics. In Isotope Tracers in Metabolic Research. Principles and Practice of Kinetic Analysis. 2nd ed. New York, John Wiley and Sons, 2005, p. 381-420
24. Leevy CM, Mendenhall CL, Lesko W, Howard MM: Estimation of hepatic blood flow with indocyanine green. J Clin Invest 41:1169-1177, 1962
25. Zoli M, Magalotti D, Bianchi G, Gueli C, Orlandini C, Grimaldi M, Marchesini G: Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 28:29-33, 1999
26. Richter S, Mucke I, Menger MD, Vollmar B: Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response. Am J Physiol Gastrointest Liver Physiol 279:G454-G462, 2000
27. Lautt WW: Regulatory processes interacting to maintain hepatic blood flow constancy: vascular compliance, hepatic arterial buffer response, hepato-renal reflex, liver regeneration, escape from vasoconstriction. Hepatol Res 7:891-903, 2007
28. Menzel J, Schober O, Reimer P, Domschke W: Scintigraphic evaluation of hepatic blood flow after intrahepatic portosystemic shunt (TIPS). Eur J Nucl Med 24:635-641, 1997
29. Wake DJ, Strand M, Rask E, Westerbacka J, Livingstone DE, Soderberg S, Andrew R, Yki-Jarvinen H, Olsson T, Walker BR: Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 66:440-446, 2007
30. Tyler FH: The effect of liver disease on adrenal cortical function. Am, J Clin Nutr 5:377-380, 1957
31. Kawai S, Ichikawa Y, Homma M: Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metab 60:848-854, 1985
32. Stewart PM, Burra P, Shackleton CHL, Sheppard MC, Elias E: 11β-Hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic liver disease. J Clin Endocrinol Metab 76:748-751, 1993
33. Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson MC, Toffolo G, Cobelli C, Rizza RA: Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab 90:3919-3926, 2005
34. Rodriguez-Laiz JM, Banares R, Echenagusia A, Casado M, Camunez F, Perez-Roldan F, de Diego A, Cos E, Clemente G: Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension: preliminary results. Dig Dis Sci 40:2121-2127, 1995
35. Rector WG Jr, Hoefs JC, Hossack KF, Everson GT: Hepatofugal portal flow in cirrhosis: observations on hepatic hemodynamics and the nature of the arterioportal communications. Hematology 8:16-20, 1988
36. Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC: Pathophysiology of portal hypertension. Gastroenterol Clin North Am 21:1-14, 1992
37. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, Hakkinen A-M, Andrew R, Wake DJ, Seckl JR, Walker BR: Body fat distribution and cortisol metabolism in healthy men: enhanced 5c-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 88:4924-4931, 2003
38. Bujalska IJ, Walker EA, Tomlinson JW, Hewison M, Stewart PM: 11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr Res 28:449-461, 2002
39. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T: Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330-3336, 2002
40. Shafqat N, Elleby B, Svensson S, Shafqat J, Jornvall H, Abrahmsen L, Oppermann U: Comparative enzymology of 11beta-hydroxysteroid dehy-drogenase type 1 from glucocorticoid resistant (guinea pig) versus sensitive (human) species. J Biol Chem 278:2030-2035, 2003
41. Stewart PM, Boulton A, Kumar S, Clark PMS, Shackleton CHL: Cortisol metabolism in human obesity: impaired cortisone: cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84:1022-1027, 1999